CORD-19:07815f7f4d5711d2c737bfc2562bd07bf4644189 / 9992-10273 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T82","span":{"begin":0,"end":281},"obj":"Sentence"},{"id":"TextSentencer_T82","span":{"begin":0,"end":281},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Mixed IC data arises in clinical follow-up studies where a tumor maker (e.g., Ca 125 in ovarian cancer) is available, a patient whose marker value is consistently on the high (or low) end of normal range in repeated testing is usually under close surveillance for possible relapse."}

{"project":"Epistemic_Statements","denotations":[{"id":"T28","span":{"begin":0,"end":281},"obj":"Epistemic_statement"}],"text":"Mixed IC data arises in clinical follow-up studies where a tumor maker (e.g., Ca 125 in ovarian cancer) is available, a patient whose marker value is consistently on the high (or low) end of normal range in repeated testing is usually under close surveillance for possible relapse."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T82","span":{"begin":0,"end":281},"obj":"Sentence"}],"text":"Mixed IC data arises in clinical follow-up studies where a tumor maker (e.g., Ca 125 in ovarian cancer) is available, a patient whose marker value is consistently on the high (or low) end of normal range in repeated testing is usually under close surveillance for possible relapse."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T13","span":{"begin":59,"end":64},"obj":"Disease"},{"id":"T14","span":{"begin":88,"end":102},"obj":"Disease"},{"id":"T15","span":{"begin":96,"end":102},"obj":"Disease"}],"attributes":[{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0008170"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"Mixed IC data arises in clinical follow-up studies where a tumor maker (e.g., Ca 125 in ovarian cancer) is available, a patient whose marker value is consistently on the high (or low) end of normal range in repeated testing is usually under close surveillance for possible relapse."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T1","span":{"begin":59,"end":64},"obj":"Phenotype"},{"id":"T2","span":{"begin":88,"end":102},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0100615"}],"text":"Mixed IC data arises in clinical follow-up studies where a tumor maker (e.g., Ca 125 in ovarian cancer) is available, a patient whose marker value is consistently on the high (or low) end of normal range in repeated testing is usually under close surveillance for possible relapse."}